Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7366756 | 1.00 | USP2 (0.45) | USP2SMN1; SMN2TP53HPGDALOX12 | |
| SCHEMBL935828 | 1.00 | USP2 (0.45) | USP2SMN1; SMN2TP53HPGDALOX12 | |
| SCHEMBL1711635 | 1.00 | USP2 (0.45) | USP2SMN1; SMN2TP53HPGDALOX12 | |
| SCHEMBL7887892 | 1.00 | USP2 (0.45) | USP2SMN1; SMN2TP53HPGDALOX12 | |
| SCHEMBL1711638 | 1.00 | USP2 (0.45) | USP2SMN1; SMN2TP53HPGDALOX12 | |
| SCHEMBL7880579 | 1.00 | USP2 (0.45) | USP2SMN1; SMN2TP53HPGDALOX12 | |
| SCHEMBL7888124 | 1.00 | USP2 (0.45) | USP2SMN1; SMN2TP53HPGDALOX12 | |
| SCHEMBL7888410 | 1.00 | USP2 (0.45) | USP2SMN1; SMN2TP53HPGDALOX12 | |
| SCHEMBL936034 | 0.95 | GRIN2D (0.43) | USP2SMN1; SMN2TP53HPGDALOX12 | |
| SCHEMBL20543621 | 0.85 | SMN1; SMN2 (0.45) | USP2SMN1; SMN2TP53HPGDALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208876-A1 | AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN | Kong, Xianqi (CA) | 2012-08-16 | — | — | US | claimed |
| EP-2454229-B1 | AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN | RISEN (SHANGHAI) PHARMA TECH CO LTD (CN) | 2017-09-13 | — | — | EP | disclosed |
| US-20160220519-A1 | AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN | LU, Jiasheng (CN) | 2016-08-04 | — | — | US | disclosed |
| US-20160220519-A1 | AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN | LU, Jiasheng (CN) | 2016-08-04 | — | — | US | disclosed |
| US-9233913-B2 | Amino acid derivatives for the treatment of neuropathic pain | Kong, Xianqi (CA) | 2016-01-12 | — | — | US | disclosed |
| US-9233913-B2 | Amino acid derivatives for the treatment of neuropathic pain | Kong, Xianqi (CA) | 2016-01-12 | — | — | US | disclosed |
| US-20140171507-A1 | AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN | Kong, Xianqi (CA) | 2014-06-19 | — | — | US | disclosed |
| US-20140171507-A1 | AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN | Kong, Xianqi (CA) | 2014-06-19 | — | — | US | disclosed |
| US-20120208876-A1 | AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN | Kong, Xianqi (CA) | 2012-08-16 | — | — | US | disclosed |
| US-20120208876-A1 | AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN | Kong, Xianqi (CA) | 2012-08-16 | — | — | US | disclosed |
| WO-2010127439-A1 | AMMO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171507-A1 | AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN | GAP43, OPRL1, NGF | USP2 3820/4885SMN1; SMN2 212/4885TP53 4529/4885 |
| US-20160220519-A1 | AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN | GAP43, OPRL1, NGF | USP2 3892/4885SMN1; SMN2 213/4885TP53 4523/4885 |
| US-20120208876-A1 | AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN | GAP43, OPRL1, NGF | USP2 3820/4885SMN1; SMN2 212/4885TP53 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.